Discover XRHealth’s role in advocating and implementing the Access to Prescription Digital Therapeutics Act, enhancing access to cutting-edge digital health solutions.

Introduction

Prescription digital therapeutics are transforming patient care. Yet, access and reimbursement remain hurdles. The Access to Prescription Digital Therapeutics Act aims to break down these barriers. But what does it really mean? And how does XRHealth pave the way for broader adoption of immersive, AI-driven treatments?

In this post, we’ll:

Break down the new healthcare policy digital therapeutics legislation.
Compare a leading competitor, CT-155, and its limitations.
Highlight XRHealth’s XR-powered solutions.
Show how XRHealth aligns with the Act’s goals.

Ready? Let’s dive in.

The Access to Prescription Digital Therapeutics Act

In late 2025, U.S. senators reintroduced the Access to Prescription Digital Therapeutics Act. At its core, the bill:

Ensures Medicare and Medicaid cover approved prescription digital therapeutics.
Clarifies coding and billing pathways for clinics.
Encourages FDA review and expedited pathways for software-based treatments.

The goal? More patients, from coast to coast—or from Sydney to Tel Aviv—can access regulated digital therapies without financial stress. It’s a big step for healthcare policy digital therapeutics in the modern era.

A New Hope: CT-155 Digital Therapeutic

Recently, Phase 3 data on CT-155 show promising results for negative symptoms in schizophrenia. Developed as a focused digital intervention, CT-155:

Targets a very specific clinical condition.
Relies on traditional app-based or web-based delivery.
Demonstrates efficacy, but under a narrow scope.

Strengths

Rigorous Phase 3 trials.
FDA pathway underway.

Limitations

Limited to one disorder.
Patient engagement can wane without immersive elements.
Clinician workflow integration is minimal.

CT-155 represents a valuable step forward—but it also highlights gaps in engagement, scalability, and clinic integration that the Access to Prescription Digital Therapeutics Act strives to address.

XRHealth’s XR-Powered Therapeutic Solutions

XRHealth takes a broader approach. By blending Extended Reality, artificial intelligence, and clinical insights, XRHealth offers:

AI-Driven Therapeutic Spaces

A suite of immersive XR environments tailored to:

Pain management
Mental health support
Physical rehabilitation
Cognitive training

These spaces adapt in real time based on patient performance and biometric feedback.

XR Clinician AI Assistant

A virtual avatar that helps clinicians:

Streamline documentation
Guide patients through XR sessions
Provide education with interactive visuals

No more juggling multiple screens—clinicians focus on care, not paperwork.

Why it matters? XRHealth addresses key hurdles in healthcare policy digital therapeutics:

Engagement: Immersive environments boost adherence.
Scalability: Cloud-based delivery fits US, EU, Australia, Israel and beyond.
Integration: Direct billing codes simplify reimbursement under the new Act.

Side-by-Side Comparison

Feature	CT-155	XRHealth
Clinical Focus	Schizophrenia (negative symptoms)	Broad: pain, mental health, rehab, cognition
Immersion Level	2D app screens	Fully immersive XR worlds
Clinician Workflow Integration	Limited	Built-in AI assistant
Reimbursement Readiness	Pending coding guidance	Aligned with Act; clear billing paths
Global Reach	Single-region trials	Multi-region platform

CT-155 scores high in targeted efficacy. XRHealth scores high in versatility, engagement, and policy alignment.

How XRHealth Champions the Act

When lawmakers crafted the Access to Prescription Digital Therapeutics Act, they aimed to:

Widen Access
XRHealth’s telehealth-enabled XR spaces mean patients can engage from home, rural clinics, or urban hospitals.
Ease Reimbursement
XRHealth collaborates with payers to map its services to CPT codes, ensuring smoother billing under Medicare, Medicaid, and private plans.
Support Clinicians
The XR Clinician AI Assistant cuts administrative work by up to 40%, so providers can focus on patient care.
Back Innovation with Evidence
XRHealth’s clinical research portal showcases ongoing trials and real-world outcomes, reinforcing FDA-ready data packages.

By tackling the hurdles of engagement, billing, and evidence, XRHealth embodies the spirit of the Act—and accelerates patient access to prescription digital therapeutics.

Conclusion

The Access to Prescription Digital Therapeutics Act marks a turning point in healthcare policy digital therapeutics. XRHealth doesn’t just comply with this vision—it leads it. With AI-Driven Therapeutic Spaces and the XR Clinician AI Assistant, XRHealth delivers immersive, scalable, and reimbursable digital treatments across regions.

The good news? Patients and providers no longer have to choose between innovation and access.

Ready to experience the future of prescription digital therapeutics?
Visit https://www.xr.health to learn more and schedule a demo.